Colorado MEDtech, Inc. Strengthens Leadership Team.

Business and Health Editors

BOULDER, Colo.--(BW HealthWire)--March 20, 2001

Colorado MEDtech, Inc. (Nasdaq:CMED), a Boulder, Colorado-based provider of advanced medical technology outsourcing services and medical imaging products, today announced that James C. Vetricek has joined the Company as Vice President of Quality and Regulatory Affairs.

Mr. Vetricek will be responsible for all quality and regulatory programs and compliance for the Company and its business units.

Mr. Vetricek has over fifteen years of extensive experience in regulatory affairs and quality assurance matters in the medical products industry. Prior to joining Colorado MEDtech, Mr. Vetricek was Vice President of Regulatory Affairs/Quality Management for the Linvatec division of CONMED Corporation, an orthopaedic products and advanced surgical instruments company. At Linvatec, he was responsible for managing regulatory affairs, clinical programs and quality operations. Prior to his experience at Linvatec, Mr. Vetricek was Vice President of Regulatory Affairs and Quality Assurance and R&D for the Ohmeda Medical Device division of The BOC Group, a developer and manufacturer of products for anesthesia and critical care.

"Jim is an important addition to our strong executive team," said Stephen K. Onody, President and CEO. "His quality and regulatory experience in the medical device industry will be valuable to Colorado MEDtech as we continue to strengthen and grow our business."

Colorado MEDtech, Inc., through its wholly owned subsidiaries and operating divisions, is a leading full-service OneSource OutSource(tm) provider of advanced medical technology outsourcing, which includes development, software, medical device communications and manufacturing services, and medical imaging, which includes critical system components and ultrasound accessories.

Forward-Looking Statements 

The statements in this news release and in the conference call that are not historical facts are forward-looking statements that represent management's beliefs and assumptions based on currently available information. Forward-looking statements can be identified by the use of words such as "believes," "intends," "estimates," "may," "will," "should," "anticipated," "expected" or comparable terminology or by discussions of strategy. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties including, but not limited to, the risk that the Company's existing level of orders may not be indicative of the level or trend of future orders, the risk that the Company may not successfully complete the work encompassed by current or future orders, the risk that unforeseen technical or production difficulties may adversely impact project timing and financial performance, the risk that the management changes will not produce the desired results, the risk of potential litigation, the risks associated with regulation by the Federal Food and Drug Administration including compliance with the Quality System Regulation, the risk that acquired companies cannot be successfully integrated with the Company's existing operations and the risk that a downturn in general economic conditions or customer budgets may adversely affect research and development and capital expenditure budgets of potential customers upon which the Company is dependent. Should one or more of these risks materialize (or the consequences of such a development worsen), or should the underlying assumptions prove incorrect, actual results could differ materially from those forecasted or expected. These factors are more fully described in the Company's documents filed from time to time with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update publicly or revise such statements whether as a result of new information, future events or otherwise.